Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies
- PMID: 36583504
- PMCID: PMC10134288
- DOI: 10.1002/cam4.5551
Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies
Abstract
Over the last decade, the emergence of several novel therapeutic approaches has changed the therapeutic perspective of human malignancies. Adoptive immunotherapy through chimeric antigen receptor T cell (CAR-T), which includes the engineering of T cells to recognize tumor-specific membrane antigens and, as a result, death of cancer cells, has created various clinical benefits for the treatment of several human malignancies. In particular, CAR-T-cell-based immunotherapy is known as a critical approach for the treatment of patients with hematological malignancies such as acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and non-Hodgkin's lymphoma (NHL). However, CAR-T-cell therapy of hematological malignancies is associated with various side effects. There are still extensive challenges in association with further progress of this therapeutic approach, from manufacturing and engineering issues to limitations of applications and serious toxicities. Therefore, further studies are required to enhance efficacy and minimize adverse events. In the current review, we summarize the development of CAR-T-cell-based immunotherapy and current clinical antitumor applications to treat hematological malignancies. Furthermore, we will mention the current advantages, disadvantages, challenges, and therapeutic limitations of CAR-T-cell therapy.
Keywords: T-cell therapy; chimeric antigen receptor T cells; hematological malignancies; immune therapy; tumor immunology.
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
All authors declare no conflict of interest.
Figures
![FIGURE 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10134288/bin/CAM4-12-7844-g003.gif)
![FIGURE 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10134288/bin/CAM4-12-7844-g005.gif)
![FIGURE 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10134288/bin/CAM4-12-7844-g006.gif)
![FIGURE 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10134288/bin/CAM4-12-7844-g002.gif)
![FIGURE 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10134288/bin/CAM4-12-7844-g001.gif)
Similar articles
-
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.Biomed Res Int. 2020 Oct 1;2020:4241864. doi: 10.1155/2020/4241864. eCollection 2020. Biomed Res Int. 2020. PMID: 33062678 Free PMC article. Review.
-
Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.Eur J Haematol. 2024 Feb;112(2):197-210. doi: 10.1111/ejh.14074. Epub 2023 Aug 6. Eur J Haematol. 2024. PMID: 37545132 Review.
-
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.Chin Med J (Engl). 2023 Oct 5;136(19):2285-2296. doi: 10.1097/CM9.0000000000002549. Chin Med J (Engl). 2023. PMID: 37358555 Free PMC article. Review.
-
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Curr Res Transl Med. 2017. PMID: 28988742 Review.
-
CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?Eur J Haematol. 2024 Jan;112(1):6-18. doi: 10.1111/ejh.14076. Epub 2023 Aug 7. Eur J Haematol. 2024. PMID: 37545253 Review.
Cited by
-
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.Int J Mol Sci. 2024 Jul 15;25(14):7743. doi: 10.3390/ijms25147743. Int J Mol Sci. 2024. PMID: 39062986 Free PMC article. Review.
-
Effectiveness of CAR-T treatment toward the potential risk of second malignancies.Front Immunol. 2024 May 2;15:1384002. doi: 10.3389/fimmu.2024.1384002. eCollection 2024. Front Immunol. 2024. PMID: 38756776 Free PMC article. No abstract available.
-
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.Front Immunol. 2024 May 2;15:1383978. doi: 10.3389/fimmu.2024.1383978. eCollection 2024. Front Immunol. 2024. PMID: 38756774 Free PMC article. Review.
-
Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy.Cell Death Dis. 2024 Apr 1;15(4):238. doi: 10.1038/s41419-024-06616-7. Cell Death Dis. 2024. PMID: 38561367 Free PMC article. Review.
-
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities.Heliyon. 2024 Jan 22;10(3):e25081. doi: 10.1016/j.heliyon.2024.e25081. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38314300 Free PMC article. Review.
References
-
- Andersen CL, Siersma VD, Hasselbalch HC, et al. Association of the blood eosinophil count with hematological malignancies and mortality. Am J Hematol. 2015;90(3):225‐229. - PubMed
-
- Maroufi NF, Vahedian V, Hemati S, et al. Targeting cancer stem cells by melatonin: effective therapy for cancer treatment. Pathol Res Pract. 2020;216(5):152919. - PubMed
-
- Astamal RV, Maghoul A, Taefehshokr S, et al. Regulatory role of microRNAs in cancer through hippo signaling pathway. Pathol Res Pract. 2020;216(12):153241. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical